Post by Clever-Access

🔭 All Was Expected — What the First Orphan JCA Reveals About the EU HTA System, and Where It Leads The tovorafenib JCA (JCA-MP-2024-06) should not surprise anyone who understands how the framework was built. That is precisely the point. Our fourth and final report in the tovorafenib JCA series takes a step back from the technical and operational detail to ask the harder question: was this outcome foreseeable from the design itself? The answer is yes — and the conformity to expectation is the finding. 📌 What the report argues: The first orphan JCA produced almost exactly the result the framework's architecture would predict. Not because anyone failed — the assessment team's conduct was rigorous and largely exemplary — but because systems tend to produce the outcomes they are designed to produce. The report traces how four structural features of the framework converge on a single missing step: the conversion of exhaustively documented uncertainty into a stated, graded degree of certainty. Until that step is taken, the decisive interpretive work is silently delegated to up to twenty-seven national bodies — the opposite of what a joint assessment was meant to achieve. Beyond methodology, the report examines the innovation signal the first JCA sends to developers of orphan, single-arm, and evidence-poor products, and what that signal may mean for European competitiveness over time. The conclusion is not pessimistic. What a design makes predictable, a design can also change. Tovorafenib is the template — not the exception. And the route to a more mature, fit-for-purpose framework is already visible. 📬 For any questions or support on JCA and/or JSC strategy, contact Clever-Access. #EUHTA #JCA #HealthTechnologyAssessment #MarketAccess #OrphanDrugs #Tovorafenib #HTAR #EvidenceGeneration #EuropeanInnovation #CleverAccess